Avid Bioservices Inc (CDMO)

[yearwax]

People, why is this so hard to understand?!? The trial was done according to RECIST guidelines. Every patient, whether receiving Bavi or not, is considered to have an objective response only after they have had a confirmatory scan. That means, by definition, that the number of objective responses for either group cannot go down; they have already had their objective responses. Let me repeat that for the ignorant, the willfully ignorant or the corrupt: the number of objective responses CANNOT GO DOWN.

Remember, the purpose of this randomized trial is to show that the group receiving Bavi has a statistically significant higher response rate than those receiving the control. Therefore, the only potential danger in the data, from a PPHM perspective, is that the number of objective responses for the control group continues to go up while the number of objective responses for those receiving Bavi stays the same. That would mean that the headline - Peregrine's Bavituximab Shows 50% Improvement in Overall Tumor Response Rate in Randomized Phase II Lung Cancer Trial – would become incorrect. However, given the fact that they have released the data when they did, they – and I – are confident this won’t be a problem. Peregrine management may be inept when it comes to protecting shareholder value, but they are scrupulously honest about the science.

As to Dew’s other equally moronic point, concerning the design of the trial not being significant or pivotal, I was about to respond to that when I read post 71881. When JR is not whining about the share price, he is capable of making valid arguments. This might be his best in a long time. He absolutely nails it.